Jeffrey Foy
Corporate Officer/Principal presso PEPGEN INC.
Posizioni attive di Jeffrey Foy
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| PEPGEN INC. | Corporate Officer/Principal | - | - |
Oligonucleotide Therapeutics Society, Inc.
 Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Corporate Officer/Principal | - | - |
Storia della carriera di Jeffrey Foy
Precedenti posizioni note di Jeffrey Foy
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| DICERNA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Formazione di Jeffrey Foy
| Northeastern University | Graduate Degree |
| University of Vermont | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 6 |
Posizioni
| Corporate Officer/Principal | 3 |
| Graduate Degree | 1 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PEPGEN INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Commercial Services |
- Borsa valori
- Insiders
- Jeffrey Foy
- Esperienza
